Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Heron Therapeutics Inc (HRTX) Price & Performance

VanEck JP Morgan EM Local Currency Bond ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

VanEck JP Morgan EM Local Currency Bond ETF vs Heron Therapeutics Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.47, while Heron Therapeutics Inc trades at $0.48 (market cap $84.50M). The key difference: VanEck JP Morgan EM Local Currency Bond ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

EMLCHRTX
Sector
Fixed IncomeHealth
52-Week High
$26.59$2.02
52-Week Low
$24.83$0.39
Market Cap
$84.50M
Enterprise Value
$182.40M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck JP Morgan EM Local Currency Bond ETF

EMLC trades at $25.47, showing minimal daily movement with a slight decline of 0.04%. Technical indicators signal a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share throughout 2026, providing steady income. Recent news highlights growing institutional interest in emerging market bonds as investors seek yield above Treasury rates.

The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market debt's attractive yield premium. However, currency risk and capital erosion concerns persist as short interest has surged 73%, indicating skepticism about long-term sustainability despite the 6.1% trailing yield.

Heron Therapeutics Inc

HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.

The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.

Returns comparison

Trailing returns across standard periods

About VanEck JP Morgan EM Local Currency Bond ETF

EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.

Read more on EMLC

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX